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ABSTRACT 
INTRODUCTION: 
             AIDS is a multifactorial disease caused by HIV virus, which 
suppresses the immune system leading to life threatening opportunistic 
infections and cancers. Without treatment the average survival time is 
around  9 – 11 yrs.The introduction of HAART therapy leads to 
decreased mortality and morbidity in developing countries.Eventhough 
the HAART therapy is beneficial in decreasing the morbidity , the 
complications of which is now emerging as a biggest problem in the 
present scenario. 
METHODOLOGY : 
       Among the patients attending CMCH ART centre ,totally 100 
patients with age between 18 – 60 yrs were included in the study.Among 
them one group on HAART with 50 patients and the rest 50 patients in 
non HAART group were equally divided.Among HAART group ,they 
were further subdivided based on regimens .All the 100 patients were 
followed up with lipid profile values at baseline,6 months and 12 months. 
These values were analyzed and compared by statistical methods . 
 
 
RESULTS :  
      As observed by the study there occurred a significant lipid 
abnormalities in patients on HAART.There  is a statistically  significant 
increase in  total cholesterol, triglycerides, LDL among the HAART 
patients at the end of one year. However there is statistically insignificant 
decrease in high density lipoproteins in HIV infected patients on 
HAART.Prevalence of dyslipidemia is more in efavirenz based regimen. 
From the results obtained in our study it is clear that the prevalence of 
dyslipidemia( elevated TC, TGL & LDL) was higher in patients on ART 
patients when compared to non ART patients (p value < 0.001). There 
was no difference in the prevalence of HDL.  
         In conclusion by monitoring the lipid parameters in  HIV patients  
to be started on HAART, better to start  with lipid friendly drugs if there 
is associated dyslipidemia, on the other hand the patients with 
dyslipidemia who was already on HAART can be switched over to lipid 
friendly regimens or we can add lipid lowering drugs . So by doing this 
we can prevent the cardio and cerebrovascular complications and thereby 
we can improve the quality of life in patients who are already 
immunocompromised. 
KEY WORDS : HIV, AIDS, HAART, Non HAART , DYSLIPIDEMIA 
INTRODUCTION 
            HIV is a lentivirus(a subgroup of retrovirus) that causes  AIDS, a 
condition  in humans which causes a progressive failure of the immune 
system that leads to life threatening oppurtunistic infections and 
cancers.Without treatment the average survival time after infection with 
HIV is estimated to be 9 – 11 yrs. 
         The immune cells infected by HIV are Helper- T cells, 
macrophages, dendritic  cells. HIV infection causes low levels of CD4+T 
cells by many mechanisms that  includes apoptosis of uninfected 
bystandercells,  direct killing of infected  cells, killing of  infected CD4 
cells by CD8 cytotoxic T cells. HIV-I has high  virulence and high 
infectivity where as HIV-II has low virulence and low  infectivity 
         The introduction of  HAART had led to a dramatic reduction in 
AIDS related  morbidity and mortality in both developed and developing 
countries. HIV  replication plays an important role in its course of 
disease. Suppression of  replication is very important to prevent HIV 
associated morbidity and mortality. 
Strict adherent to ART therapy will cause adequate suppression. 
Since the  Introduction of HAART patient started to have a improved 
quality of life but however comorbid problems have  been emerged. 
Dyslipideamia, insulin  resistence & Diabetes are some of the metabolic 
complications of  long term  use of HAART. 
AIMS AND OBJECTIVES 
 
Aim of the study 
 To analyze the  lipid abnormalities in adult HIV patients on 
HAART therapy 
Objectives 
1) To  determine  the  prevalence  of  dyslipidemia in  HIV patients  on   
HAART therapy 
2) To  compare  the  lipid  profiles of  HIV patients  on HAART therapy  
and   those  who are  not  started  on  HAART therpy. 
 
  
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
HISTORY OF HIV  
 
   In 1970s a syndrome called fading kitten syndrome caused by 
feline  leukemia virus characterized by immunodeficiency was identified. 
 
 In 1981 the virus Human T cell leukemia virus was discovered and 
found to  cause T cell leukemia in human beings. Also in 1981 
pnenmocystis carinii  pneumonia  was reported in  homosexual men. In 
1982 the hemophiliacs has  contracted this disease. In may 20
th
 1983 a 
retro virus was isolated from AIDS  patient with GLA by Luc montagnier 
and he named it as lymphadeopathy  associated virus. Another RETRO 
virus was isolated from AIDS patient similar to HTLV and they called it 
as HTLV – III in may 4
th
 1984 by Robert  C  Gallo and his colleagues. 
 
 In 1984 the industrialised  countries screening for HIV in blood 
donors. The working definition for AIDS was given by centre for disease 
control in 1986. 
 
Also in this same year the International committee for taxonomy of 
viruses -7 has  renamed HTLV- III / LAV as Human Immuno deficiency 
virus 
EPIDEMIOLOGY 
 
HIV infection is global pandemic. According to UNAIDS there will be 
33.3million  Individuals were living with HIV infection at the end of 
2009. About more than  95% of the people living with HIV/AIDS resides 
in low and middle income  countries, of that 50% will be female and 
2.5million are children less than 15  years. In 2009  the global AIDS 
deaths was totaled around 1.8million that includes  2,60,000 children less 
than 15years. HIV epidemics has occurred in waves in  different regions 
of the world. More than 2/3
rd
 of all peoples with HIV infections  live in 
sub Saharan Africa that has only 10-11% of the worlds population, within  
that the southern Africa is worst affected. Heterosexual exposure is the 
most  common mode of transmission there. 
 In east, south and south east Asia are mostly affected. Among the 
Asian  countries, Thailand has an adult seroprevalance  rate of >1%. In 
Bangladesh and  Pakistan the prevalence has increased very much 
 In united states as of jan 2010, the total cases estimated was 
1,108,611.  Around 1.1 million individuals were living with HIV 
infection of which 21% are  unaware of the infection. Around 48% were 
men who have sex with men. An estimated 56,000 individuals are newly 
infected each year. 
 In India the first case of AIDS was reported in the year 1986. 
2.4million  Peoples are living with this condition. About 1,70,000 AIDS 
related deaths  happened. New HIV infections has declined by more than 
50% over the past   decade from 2.7 lakh in 2000 to 1.2lakh in 2009. 
Adult HIV prevalence in India is  0.27% as of 2011. Over all India’s HIV 
epidemics slowing down with 57% decline in new infections between 
2000-2011 and a 29% decline in AIDS related deaths between 2007-
2011. 
 
 MORPHOLOGY 
HIV as mentioned previously is a RETRO virus belonging to 
subfamily of LENTI  virus. HIV virion is an icosahedral structure that 
contains numerous external  spikes which are formed by 2 major 
enveloped proteins namely gp120 and gp41. 
 
REPLICATION OF HIV 
 HIV is a RNA virus. Replication cycle of HIV starts with the 
binding of   Gp120 protein to its receptor on the host cell surface that is 
the CD4 helper cells. As soon as the gp120 binds to CD4 there will be a 
change which facilitates binding to one of its co-receptors namely CCR5 
and CXCR4. Dendritic cells also will  facilitate the binding of the virus to 
the CD4 cells.  
         After the binding of gp120 with CD4 cells there will be a fusion 
with the host cell membrane through gp41 followed by coiling that brings 
virion and target cell  together. Following fusion the complex composing 
viral RNA and enzymes  surrounded by a capsid protein is released into 
the cytoplasm of the target cell. During the traversion of the 
preintegeration complex to the nucleus from the  cytoplasm the viral 
reverse transcriptase enzyme catalyses the reverse  transcription of RNA 
to DNA and the protein coat release the double stranded  proviral  
HIVDNA. The viral DNA access the nucleus pore and is exported from         
cytoplasm to the nucleus. In the nucleus it is integrated into host cell 
chromosomes by the enzyme integrase. The replication and pathogenesis 
of HIV  disease is mainly mediated by cellular activation. Unless this 
cellular activation  takes place there won’t be efficient integration of viral 
DNA to the host cell.  This cellular activation is also mainly responsible 
for transcription of   proviral DNA into genomic RNA or mRNA.  After 
transcription there will be translation of  HIV mRNA into proteins which 
undergoes various modifications, then the  proteins, enzymes, genomic 
RNA forms the viral particle. Finally the cleavage of   gag  pol   precursor 
that yields a mature virion is catalysed by virally  encoded  protease. 
 
 
HIV GENOME:  
HIV  - I contains gene that encodes protein  
 Gag    -  core 
 Pol    -  
Env    -  
 Also contains 6 other genes (tat, rev, nef, vif, vpr, vpu) which plays 
an  important role in pathogenesis of HIV disease.
The main gene different
has no vpu and  HIV
MOLECULAR HETEROGENECITY OF HIV:
 There are variable degree of differentiation ranging from 2% to 
50% in  coding sequences of viral envelope protein. HIV virus can evolve 
by several means 
recombination and gain and 
protease processing of viral protein reverse 
transcription and integration  
envelope glycoprotein 
 
iation between HIV-I & II is that HIV
-I has no vpx.  
 
that includes basal substitution, insertion, deletion, 
 loss of glycosylation sites. The balance 
 
 
-II 
between immune pressure and functional  constrains on proteins 
influences the regional level of variation within proteins. There are four 
groups of HIV-I , group-M the most common and the group-O  relatively 
rare followed by group-N and group - P. on comparison with other 
LENTI  viruses HIV-I is very closely related to  viruses isolated from 
chimpanzees and gorillas. The M group comprises of 9  subtypes as well 
as circulating recombinanat forms. These CRFs are formed by  two 
subtypes that infect the same individuals which then recombine that 
creates  a virus with a selective advantage. 
 About 7 strains of HIV has a global prevalence of >2.5% which 
accounts for  majority of infections. Subtype C virus are the most 
common form worldwide that accounts for 50% prevalence of infections. 
In Asia  HIV-I isolates of CRF01_AE  lineage and subtypes C and B 
predominates. The most common infection in south  and south east Asia 
is by CRF01_AE, but subtype C is common in India. Various  faces of 
HIV that includes multiple subtypes, CRFs, continuous viral evolution 
has  implications for different rates of disease progression, response to 
therapy and  drug resistance  
 
  
RISK GROUPS AND MODE OF TRANSMISSION 
HIGH RISK GROUPS: 
    Female sex worker 
    Men who have sex with men 
    Transgender 
    Intravenous drug abusers 
 
 BRIDGE POPULATIONS:  
    Truckers 
    Migrant populations 
MODE OF TRANSMISSION: 
    Heterosexuals – 88.2% 
    Parent to child – 5% 
    Homosexuals – 1.5% 
    Intravenous drug abusers – 1.7% 
    Blood and blood products – 1% 
    Not specified – 2.7% 
 
PATHOPHYSIOLOGY AND PATHOGENESIS: 
The hallmark of HIV disease is a profound immunodeficiency  that 
results from a quantitative and qualitative deficiency of the T  
lymphocytes called as helper T cells that is CD4 cells. There are two  co-
receptors that HIV uses for its binding, fusion and entry. They are  known 
as CCR5 and CXCR4. 
The various mechanisms that involved in cellular deletion  and 
immune dysfunction are direct infection, destruction of the cells by  HIV, 
immune clearance of infected cells, aberrant cellular activation and 
activation induced cell death. Both viral and immunogenic events which  
occurs during the full course of the disease are complex. The  
pathophysiologic events of HIV disease are multifactorial and they are 
different at different stages of the disease. 
EVENTS IN HIV INFECTION 
 
The disease is  primarily  transmitted through sexual contact and   
so the main site of portal of entry for HIV virus is through mucosal 
surfaces. This includes oropharynx, rectum, genital mucosa. These are  
the areas that are rich in langerhans and dendritic cells which traps the  
antigens and viral particles. The antigens are trapped by the dendritic  
cells through DC-SIGN receptors which is involved in transportation of 
virus to the draining lymphoid tissues, within few hours after exposure  to 
the virus there will be quick multiplication of virus which may be  
detected in the draining lymph nodes. The minimum time period  required 
for infection is two hours contact period between simian  
immunodeficiency virus and vaginal mucosa. After within few days the  
virus can be detected in  nearby lymphocytes,monocytes and then in  the 
regional lymphoid tissue. Followed that  the primary viremia leads  to full 
dissemination of virus throughout the body.  
ESTABLISHMENT OF CHRONIC AND PERSISTENT 
INFECTION: 
PERSISTENT VIRAL REPLICATION: 
Eventhough the humoral and cellular immune responses  are 
activated following primary infection the virus escapes immune  
mediated clearance and is never completely eliminated from the body.  
Within a median of ten years a chronic infection sets in which is a 
hallmark of HIV disease,followed which patient becomes ill. Throughout  
his chronic infection the viral replication takes place continuously which  
can be detected by highly sensitive assays in the circulation and the  
lymphoid tissues. Chronicity seen in HIV infection are also seen in HCV 
and HBV infection,but the immune system is not the target for these 
viruses. 
EVASION OF IMMUNE SYSTEM CONTROL: 
This virus evades from the immune system by various  
mechanisms. The main one is by establishment of continuous viral  
replication with generation of viral diversity via mutation and 
recombination. The clones of CD8 cytotoxic T cells that are produced and 
expanded during primary HIV infection are deleted or made  
dysfunctional due to the persistent viral replication. Another mechanisms 
by which the virus escapes from immune system is by  down regulation 
of HLA class I molecules on the surface of HIV infected  cells by nef 
protein of HIV which results in the lack of recognition. The  three 
mechanisms by which HIV evades from neutalising  responses are  
hypervariability in the primary sequence, extensive glycosylation and  
masking of neutralising epitopes. Another important mechanism of 
evasion is sequestration of infected cells in immunologically privileged  
sites such as central nervous system. Since HIV primarily infects CD4 
cells and so this loss of those cells have profound negative  consequences 
for the immunologic control. This evasion of HIV from the immune 
response allow the formation of a pool of latently infected  cells which 
cannot be eliminated by virus specific cytotoxic cells, so HIV  succeeds 
in putting  a strong basement creating a state of chronic  infection 
RESERVOIRS OF  HIV INFECTED CELLS: 
In all HIV infected indivuals there will be pool of latently  infected 
resting CD4 cells which serves as atleast one component of  persistent 
reservoir of virus. There are two latencies that are pre and  post 
integration latencies.  Eventhough the plasma viremia is  suppressed to 
less than 50 copies of HIV RNA/ ml by potent  combination of ARTs, 
this pool of latently infected cells persists and  produce replication 
competent virus. The main reservoir for HIV  infected cells includes 
lymphoid tissue, the peripheral blood and CNS.  The major drawbacks for 
the eradication of virus is mainly by these  persistent reservoir of  
infected cells at various latent stages.  
LYMPHOID ORGANS AND HIV PATHOGENESIS: 
 
The main site for multiplication, establishment and  progression of 
HIV infection are the lymphoid tissues. Eventhough the  plasma viremia 
is accounted for the level of disease activity, the viral  replication mainly 
occurs in lymphoid tissues. The cellular response and  immune activation 
are mainly reflected by lymphadenopathy. Our  recent studies have 
focused on GALT that is Gut Associated Lymphoid  Tissue, where the 
earliest viral replication occurs. Normally in the early  stages of HIV , the 
germinal centre is generally preserved. The follicular  dendritic cells traps 
the antigens and present it to the B cells which is  the normal physiologic 
function. In case of HIV the trapped virions  causes secretion of 
proinflammatory cytokines such as IL1 beta, TNF  alpha, IL6 which will 
upregulate the viral replication. CD4 helper cells  which goes into 
germinal centres  are susceptible to infection by these  trapped virions. So 
in HIV infection the normal physiologic function of  immune system is 
affected. As the disease progress the germinal centre which was 
preserved early will undergo disruption and swelling, finally to cell death. 
In the advanced stage of disease there is complete disruption and 
resolution of FDC finally goes into stage of burn out.  This destruction of  
lymphoid tissue effects both to inability to control  replication and 
inability to make immune response.  
ROLE OF CYTOKINES IN HIV PATHOGENESIS 
Cytokines which are the components of immune system  play an 
important role in regulation of HIV expression. The cytokine  involved in 
the induction and enhancement of HIV expression are IL1,  IL2, IL3, IL6, 
IL18, IL12, TNFalpha, TNFbeta, GM-CSF. In these IL18 play  an 
important role in development of HIV associated lipodystrophy  
syndrome. TNFalpha, IL1beta and IL6 are the potent inducers of HIV  
expression. IFNalpha, IFNbeta, IL32 suppress the HIV replication. While  
TGFbeta, IL4, IL10, IFNgamma will induce or suppress HIV expression 
depending on the system involved. The elevation of TNFalpha and IL6  
are demonstrated in plasma and CSF while TNFalpha, IL1beta,  
IFNgamma,IL6 are demonstrated in the lymph node. HIV replication is  
controlled by endogenous cytokines which acts synergistically in an 
autocrine and paracrine manner. Finally the secretion of some  
proinflammatory cytokines is a result of aberrant immune activation  seen 
associated with HIV infection. 
GENETIC FACTORS IN HIV PATHOGENESIS 
 
Several genetic variations have been now identified in  human 
beings that influence the risk of acquiring HIV, rate of disease,  
progression, virological control and immune response. There  are  
polymorphisms identified in genes in the MHC locus, chemokines ,  
cytokines and other host factors. Recently they have identified  
polymorphisms  within the HLA-B and HLA-C which is associated  
approximately 15% variation in viral load during the asymptomatic  
period. In some individuals MHC Class I and class II will predispose 
them  to an immunopathogenic response particularly in some tissues like 
CNS, Lungs or against some HIV infected cell types such as 
macrophages,  dendritic cells, langerhan cells. There is increased risk of 
transmission of HIV infection among heterosexual Zambian couples who 
have an alleles  sharing at HLA-B locus. Also founded HLA 
heterozygosity for class-I loci are  associated with delayed onset AIDS in 
HIV, where as in HLA  homozygosity it was a reverse. Another gene 
called transporter  associated with antigen processing (TAP gene) play an 
important role in predicting the outcome of HIV infection. It is also noted 
that  individuals with haplotype 8.1 also been correlated with rapid 
decline in  CD4 T cells. Recent studies shows the single nucleotide 
polymorphism (SNP) in the killer immunoglobulin like receptor (KIR) 
was found to be  strongly associated with rapid progression to AIDS. The 
best example  for a genetic factor which influences HIV infection and 
pathogenesis  is related to the gene which codes for CCR5 the major HIV 
co-receptor. There are individuals who remains uninfected even though 
after  repeated sexual exposure to HIV even though in high risk situation. 
These individuals were found to have high resistance with R5 strins of  
HIV-I but they were readily infected with X4 strains. On various analysis  
these individuals inherited a homozygous defect in the gene that  encodes 
for CCR5. They have a homozygous defect for CCR5 32 allele. 20% of 
European individuals are heterozygous for CCR5 32 allele and  has 
partial resistance or a delayed disease course. Cohort studies from 
western, central Africa and far east asia has absent CCR5 32 allele 
IMMUNE RESPONSE TO HIV 
Both humoral and cellular immune responses play an important  
role in HIV disease. These immune response are directed against  variable 
antigenic determinants of HIV. 
HUMORAL IMMUNE RESPONSE 
Usually the antibodies to HIV will appear within 3-6 weeks Almost 
invariably within 12 weeks of primary infection. Usually the neutralizing 
antibodies appear after the initial decrease in plasma viremia. The 
antibodies that are detected first are those against envelope gp41 followed 
by gag protein p24 and gag precursor p55, gp 120 and gp 41 are the only 
enveloped proteins that elicit neutralizing antibodies. The neutralizing 
antibodies appears in first 6 months, but viruses escapes these antibodies. 
There are 2 types of neutralizing antibodies one is type specific 
antibodies that appears early  infection and they neutralize the viruses of a 
given strain. The other one is group specific neutralising antibodies that 
appears late in infection, which they neutralisie a wide variety of HIV. 
There are  2 types of group specific neutralising antibodies one directed 
towards  the CD4 binding site of gp120  and those binding to proximal 
region of  gp41. Antibodies directed against gp120 and gp41 also 
participate in  antibody dependent cellular cytotoxicity mediated  killing 
of HIV infected  cells. There is a entity called bystander killing in which 
the anti gp130  antibodies kills uninfected CD4 T cells complement also 
play an  important role in humoral immune response. 
CELLULAR IMMUNE RESPONSE: 
Cellular immunity is mediated by CD4 T cells and CD8 T cells. In  
this CD4 T cells plays  an important role in immune response by helping  
HIV specific B cells and CD8 T cells and of directly killing HIV infected 
cells. CD8 T lymphocytes cause the lytic destruction of target cells.  
There are 2 types of cytotoxic T lymphocytes the first type directly 
lyses  the target cells without prior invitro stimulation, the other type  
reflects the precursor frequency of cytotoxic T lymphocytes. It is also 
found that there is direct relation between the levels of CD8 T cells 
capable of producing IFN-gamma to HIV antigen and RNA levels. Some 
of the forms of cell mediated immunity to HIV described are CD8 T cell 
mediated suppression of HIV replication, antibody dependant cellular  
cytotoxicity and NK cell activity. 
FACTORS INFLUENCING HIV DISEASE PROGRESSION 
 HOST FACTORS 
Old age peoples have a rapid progression of the disease, but it was  
an independent predictor in IV drug abusers. The gender do not have any 
major  influence over the disease progression. Ethnicity also does’nt have 
any influence.  It has been studied that 5% of HIV patients will be 
clinically stable for about 10 or  more years after seroconversion and they 
are called as long term survivors or long  term non progressors.  
COFACTORS 
HIV patients with CMV seropositivity were found to have 2-4 fold  
higher risk of disease progression. This states that CMV is a cofactor in 
HIV patients which leads to disease progression. There is no clear cut 
data that EBV , HHV6, hepatits B, acts as a cofactor. 
DEFECTIVE CORECEPTORS 
To infect a cell HIV needs CD4 receptor. Another receptor needed 
to  bind and infect the cells are called chemokine receptor named CCR5. 
In many  individuals this CCR5 carry a mutant gene delta32 deletion. If 
the persons are  homozygous to delta32 then they found to have less risk 
for the infection with  HIV. 
SDF-1 GENE MUTATION 
Stromal derived factor-1 is a cytokine which normally binds to  
CXCR4. Individuals having mutation of the gene that produces SDF-1 
are more  resistant to infection.  
OTHER POTENTIAL COFACTORS 
 
Association between smoking and CD4 lymphocyte loss or more  
rapid disease progression were founded in some studies. In developing 
countries  it was studied that malnutrition may accelerate the HIV disease 
progression. 
MARKERS FOR HIV DISEASE PROGRESSION 
 
Certain measurable traits helps in disease staging and predicting  
susceptibility to opportunistic infections. 
 
 
BETA2 MICROGLOBULIN 
It is a non specific marker of immune activation. High titre levels 
are  seen in association with disease progression. Also higher levels are 
found in  various viral infection and in patients with lymphoma. 
NEOPTERIN 
Derived from macrophages and B lymphocytes. It is estimated 
using  liquid chromatography and radio immunoassay. It  also predicts the 
disease  progression. Other conditions having elevated neopterin levels 
are collagen  vascular disorders, malignancies and some infection. 
s IL- 2R 
            High levels of s IL -2R found in patients with AIDS and it 
correlate  negatively with CD4 cell counts. 
SOLUBLE CD8 
            It is an early marker of HIV infection and levels correlate with 
number of  CD8 lymphocytes. 
ANTI p 24 ANTIBODY 
             Poor prognosis is seen in patients with declined anti p24 
antibody. 
ANTI gp 120 ANTIBODY 
             Absence of the antibody is related to disease progression. 
 
 
p24 ANTIGEN 
           It is transiently seen in acute stages of HIV infection and in latent 
stages of  HIV disease. A low CD4 count with p24 antigenemia is very 
strong predictor of disease progression. 
SYNCITIUM INDUCING PHENOTYPE 
 
           Some of the HIV isolates who have syncitium inducing capacity 
are seen in  later course of the disease. 
CD38 POSITIVE CD8 T CELLS 
 
          The increased percentage of CD38 positive CD8 T cells reflects a 
high viral  load which indicates the disease severity. 
HIV RNA DETERMINATION 
 
            Plasma RNA is measured by RT – PCR , branched DNA assay or 
nucleic acid sequence based amplification. These assays can even detect a 
very low viral levels of 20 to 50 molecules. One of the indication for 
starting ART is plasma viral load of more than 30,000 copies/ml by 
bDNA assay and more than 55,000 copies/ml by RT PCR. Every 3 to 4 
months of viral load monitoring is necessary after starting  ART. 
 
MONITORING CD4 T LYMPHOCYTE COUNT  
         Progressive CD4 depletion is hall mark of HIV disease. Lower 
levels of CD4 indicates severity and serious immunodeficiency .various 
methods for counting CD4 T lymphocytes are flow cytometry and 
dedicated cytometry. The gold standard is flow cytometry. 
TERMINOLOGY OF UNTREATED HIV DISEASE 
PROGRESSIVE GLA 
The PGLA is a manifestations of early stage of HIV. It should be 
differentiated  from other diseases  causing  lymphadenopathy such as 
infections and   lymphomas.  
AIDS RELATED COMPLEX 
Now this terminology was abandoned. This is usually a 
manifestations of middle stage of HIV disease.  
AIDS 
This is the last stage, the centre for disease control and prevention 
published in September 1982 was revised once again to have additional 
conditions recognized as the late stage of HIV disease manifestations. 
  
Table : 1 CDC CLASSIFICATION SYSTEM FOR HIV INFECTED 
ADULTS AND ADOLESCENTS: 
 
CD4 CELL 
CATEGORIES 
CLINICAL CATEGORIES 
A 
ASYMPTOMATIC, 
ACUTE HIV, 
Or PGL 
B 
SYMPTOMATIC 
CONDITIONS, 
NOT A or C 
C 
AIDS- 
INDICATOR 
CONDITIONS 
>=500 Cells/ 
microliter 
A1 B1 C1 
200-499 cells/ 
micro liter 
A2 B2 C2 
<200cells/ 
microliter 
A3 B3 C3 
  
In the above mentioned, category B symptomatic conditions are defined 
as that it should meet  at least 1 of the following 
1. They are attributed to HIV infection or indicate a defect in cell 
mediated immunity 
2. They are considered to have a clinical course or management that 
is complicated   by HIV infection.  
 
Table : 2 WHO CLINICAL STAGING  
 
 
DIAGNOSIS  OF HIV INFECTION 
The standard screening test for the detection of HIV is by ELISA 
which has a sensitivity of more than 99.5%.  But however the 
confirmatory test in the western blot which detects multiple antibodies to 
HIV proteins. Other tests are DNA PCR, RNA PCR, bDNA assay and 
P24 antigen capture assay. 
GUIDELINES BY NACO FOR HIV DETECTION 
STRATEGY I 
This covers blood donor screening. A single ELISA is done, if it is  
found to be negative the donor serum is considered free of HIV, if it is 
positive it is  not informed  to donors. 
STRATEGY II 
This is mainly for surveillance and diagnostic purposes. If the first  
ELISA is negative then the sample is considered negative, in contrast if 
the first  sample is positive then the second ELISA is done and the test is 
reported as  positive when  both the tests are positive.  
STRATEGY III 
This is used to diagnose asymptomatic individuals. In this strategy 
a  third reactive test is needed before reporting a positive result.  For 
symptomatic persons the sample should be reactive with two different 
kits For asymptomatic persons the sample should be reactive with three 
different kits 
STRATEGIES FOR ASYMPTOMATIC PERSONS 
 
 
 
In practice a clinical/laboratory testing algorithm is required that employs 
more than one assay. This involves combination of two or more tests that 
use different testing principles, and which offer an increased combined 
sensitivity and specificity.  
  
    The tests should be definitely followed up by western blot or by DNA 
PCR if  the report is considered as equivocal. After confirming with 
laboratory tests the  iniation of ART begins 
 
 
ANTIRETROVIRAL THERAPY           
 Indian government launched free ART program on 1
st
 April 2004. 
There are  about 18.13 lakh people living with HIV registered at 400 
ART centers all over the  country till  march 2013. At present there are 
6.5lakh people on 1
st
 line ART. A  greater decrease in deaths are noted in 
many states where significant scale up  of ART services are achieved. 
With the current pace it is estimated around 50,000  to 60,000 deaths will 
be averted annually in next 5 years. 
GOALS OF ART 
 To improve the quality of life 
 To reduce the HIV related morbidity and mortality 
 To provide maximal and durable suppression of viral load 
 To restore and (or) preserve immune function 
      Before starting the patients should be assessed clinically by  
 Clinical Stage of HIV infection 
 The patient’s past illness 
 Current HIV related illness 
 Determine the need for ART and OIs prophylaxis.Find out 
other co-existing medical conditions and treatment that 
influence the choice of therapy 
 
MECHANISM OF ANTIRETRO VIRAL THERAPHY 
 
 
 
  
Table : 3 INDICATIONS FOR STARTING ART 
 
 
  
 
 
The optimum time for the ART to be started is before the patient becomes 
unwell  or presents with the first OI. The CD4 count should be assessed 
after stabilisation  of any concurrent illness because the absolute CD4 
count can vary with illness. 
The patients should be started on ART as soon as possible when CD4 
falls below  350. The  CD4 count should be used as a supplement for 
determinig the stage of  the  disease. All HIV confirmed persons should 
be referred to ART centres for  registration into care and screening for 
medical eligibility for ART by CD4 test and  other baseline 
investigations. Don’t delay ART initiation if the patient is clinically  
eligible according to the WHO clinical staging. CD4 monitoring is an 
important event for the HIV patients who are started with  ART, so that it 
will enables the patients adherence, response to therapy. 
Table : 4 FOLLOW UP SCHEDULE: 
 
 
Pre ART care is defined as the period where an HIV positive person does 
not  medically require the initiation of ART. Patients who do not require 
ART should be counseled for a good healthy living habits and 
environment and should be linked with health providers and facility 
centres . Following  steps are recommended for monitoring patients who 
are not eligible for ART. 
1. Baseline screening of CD4. 
2. Baseline lab assessment that includes CBC, ALT/AST, ALP, urinalysis. 
3. Annual PAP smear screening for women 
4. HBsAg and HCV screening for IDUs. 
5. Any other relevant investigations and screening for TB at every visit. 
Follow up visit for pre ART is very much important to assess the status of 
the patient. 
        Another important  task in managing the pre ART patients are 
educating the patients. Since many of the patients once informed that 
their count is adequate not to be started on ART, they wont come 
properly for the follow up, so they must be informed to return back to 
ART centre once if they feels not well or any new symptoms develop 
such as difficulty in swallowing, severe unexplained fever, unexplained 
diarrhoea, severe cough with expectoration, hemoptysis, altered 
sensorium or seizures.  
Table : 5 CURRENTLY AVAILABLE ANTIRETROVIRAL 
MEDICATIONS AND DRUG CLASSES 
 
NRTI NNRTI PROTEASE 
INHIBITORS 
INTEGRASE 
INHIBITORS 
 
MATURATION 
INHIBITORS 
FUSION 
INHIBITORS 
Zidovudine 
 
 
Nevirapine Saqunavir Raltegravir Maroviroc Enfuvirtide 
Didanosine 
 
 
Delavirdine Ritonavir    
Stavudine 
 
 
Efavirenz Indinavir    
Lamivudine 
 
 
Etravirine Nelfinavir    
Abacavir 
 
 
 Lopinavir/ 
Ritonavir 
   
Tenofovir 
 
 
 Atazanavir    
Emtricitabine 
 
 Fosamprenavir    
Zalcitabine 
 
 
 Tipranavir    
 
 
 
 Darunavir    
 
NRTIs are analogues of naturally occurring deoxynucleotides, thymidine, 
adenosine, guanosine, cytosine and cytidine. All NRTIs are converted 
into triphosphate forms by intracellular phosphorylation. The main 
mechanism by which the NRTI inhibits viral replication is by due to its 
lack of 3 hydroxyl group on the deoxyribose moiety, that prevents the 
further addition of nucleotides to the grouping DNA chain. 
 In contrast the NNRTIs inhibits binding to HIV reverse 
transcriptase, and competitively inhibits the enzyme and thereby prevents 
the normal movement of protein domain required for DNA synthesis. 
 
  
GENERAL PRINCIPLES OF PHARMACOKINETICS AND 
PHARMACODYNAMICS  
PHARMACOKINETICS 
This process provides information related to the bioavailability of 
the drugs, the degree of protein binding, volume of distribution, 
elimination half life. 
Gastric PH plays an important role in absorption of antiretroviral 
drugs particularly the protease inhibitors, the area under curve of which is 
decreased more than 75% in the presence of proton pump inhibitors, 
which should not be coadministerd. The volume of distribution is the 
relation between total amount of drug in the body and its concentration in 
the plasma. It is influenced by extent of plasma protein binding. Plasma 
protein binding is either to albumin or alpha-1-acid glycoprotein. Protein 
binding varies significantly with antiretrovirals with NNRTIs that are 
highly protein bound. 
  
PHARMACODYNAMICS 
  It is the relation between drug concentration and the 
pharmacological response in terms of efficacy. The concentration of a 
drug should produce a  effect without producing any toxicity and is 
termed as therapeutic range. It mainly deals upon the therapeutic effect, 
side effects, and toxicity. 
 
BIOCHEMISTRY OF LIPOPROTEINS 
The dietary fats and lipids synthesized from liver and adipose 
tissue should be transported to various tissues, due to its insolubility it 
should be transported by associating non polar lipids with amphipathic 
lipids and proteins. 
The major composition of lipoproteins are lipids, proteis and a few 
amount of carbohydrates. Lipid content in lipoproteins are mainly of 
triacylglycerol, and phospholipids, cholesterol, cholesterylesters and 
some free fatty acids. The protein moiety of lipoproteins is called 
apolipoprotein. The major plasma lipoproteins are chylomicrons, very 
low density lipoproteins, intermediate density lipoproteins, low density 
lipoproteins and high density lipoproteins. They are disseminated among 
themselves by lipid content, density, size and proteins on their surface. 
Usually the chylomicrons and VLDL are not considered to be atherogenic  
but the remnants of both of them namely chylomicron remnants and IDL 
are believed to be atherogenic. In liver cholesterol is excreted into bile, 
either directly or indirectly or after conversion into bileacids. Also it is 
transported from the periphery to the liver by the process called reverse 
cholesterol transport. 
       Another lipoprotein called Nascent high density lipoprotein are 
mainly secreted by the intestines and the liver and they will go for a 
modification which will becomes HDL2 and HDL3. They also play a 
very important role in cholesterol transport back into the liver. Many 
studies also find that triiodothyronine and insulin will increase the 
binding of LDL. 
  
Table : 6 CLASSIFICATION OF LIPOPROTEINS:
 
 
 
Table : 7 CLASSIFICATION OF APOLIPOPROTEINS:  
 
 
APOLIPOPROTEINS 
LIPOPROTEINS Mol.             
Mass 
(Dalton) 
METABOLIC  
FUNCTIONS 
apo  AI HDL,  
Chylomicrons 
28,000 Structural 
component of 
HDL, LCAT 
activator 
apo AII HDL,  
Chylomicrons 
17,000 Unknown; 
facilitates transfer 
of other apos 
apo B48 Chylomicrons,  
Chylomicron 
remanents 
2,60,000 It assembles the 
chylomicrons from 
the small intestine 
apo B100 VLDL, IDL, LDL 5,50,000 
 
It assembles and 
secretes VLDL 
from the liver 
Apo CI   Chylomicrons, 
VLDL, HDL 
7,600 VLDL receptor and 
liver uptake of 
chylomicrons are 
inhibited 
  
TRANSPORT OF EXOGENOUS LIPOPROTEINS 
 Normally the individuals with no dyslipidemia will dispose the 
dietary fat into the blood within 8 hrs, but the individuals who have 
dyslipidemia and especially those having increased fasting VLDL will 
have intestinally derived lipoproteins upto 24 hrs after the meal taken 
lastly. 
 In the human intestine the triglycerides and cholesterols taken by 
the diet are incorporated into chylomicrons. The content of chylomicrons 
are mainly by phospholipids, free cholesterol, apoB 48, apoAI, apoAII 
and apoAIV. Then the chylomicrons are transported through the thoracic 
duct into the circulation. ApoC proteins are transferred from HDL to the 
chylomicrons in the plasma, in capillary endothelial cells of fat and 
muscle, the triglycerides are hydrolysed by lipoproteinlipase which 
requires apoCII, where as the modulation of triglycerides hydrolysis is 
done by apoCIII. As a result of all above mentioned sequences the dietary 
triglycerides are transported to muscle and adipocytes as fatty acids and 
liver takes up the cholesterol from the diet where it uses it for bile acid 
formation and resecreted into circulation as lipoprotein cholesterol or into 
the bile. 
 
 Any abnormality that happens in transport or metabolism of 
chylomicrons will result in atherosclerosis. The main mechanism by 
which the delivery of cholesterol to the artery takes place  is by the delay 
in their removal from plasma and elevated chylomicrons and their 
remnants postprandially. 
TRANSPORT OF EXOGENOUS LIPOPROTEINS 
  
TRANSPORT OF ENDOGENOUS LIPIDS 
  This includes transport of lipids from the liver to peripheral tissues 
and viceversa. Triglycerides are formed from fattyacids in the liver which 
are picked up from plasma or by denova synthesis from liver. The liver 
can also synthesise cholesterol. Then these lipids are made together with 
both phospholipids and  apoB100 into VLDL and are secreted into the 
plasma. 
 The size of the VLDL is determined mainly by triglycerides. In 
conditions like calorie excess, diabetis mellitus, alcoholic consumption a 
very large triglyceride rich VLDL is secreted. 
 Even though the principal hepatic lipoproteins is VLDL in most 
individuals, both VLDL and cholesteryl enriched IDL can be secreted by 
liver in conditions with combined hyperlipidemia. LDL is formed mainly 
from smaller and more dense VLDL. The only protein which remains on 
the surface of LDL particle is apoB100. 
 
 
 
 
The main determinant of half life of LDL in plasma is by LDL 
receptors( apoB100, apoE) availability. Liver takes up the most of plasma 
LDL and the remaining ones are transported to peripheral tissues that 
includes adrenals and gonads where steroid harmone synthesis takes 
place. The highest concentration of LDL receptors in our body is seen in 
adrenals. Goldstein and Brown are the forerunner who charecterised the 
LDL receptors role in cholesterol metabolism. The two main risk factors 
for atherosclerosis are increased plasma LDL and apoB100. On 
incubation with cultured macrophages or smooth muscles the normal 
LDL  will not cause foam cell formation, but on lipid peroxidation it 
becomes a ligand, scavenger receptor pathway. The endothelial cells and 
macrophages that have scavenger receptors will cause uptake of modified 
lipoproteins which results in cholesterol laden foam cell formation. In 
addition it stimulates the secretion of cytokines and growth factors by 
various cells that synthesise and secrete collagen. 
 In atherogenesis the role of VLDL is uncertain. The main reason is 
due to inverse relation between decreased level of HDL and increased 
level of triglycerides and is of possible which hypertriglyceridemia may 
not cause direct atherogenesis but the surrogate markers can cause. Also 
the cholesteryl esters  enriched with VLDL will cause foam cell 
formation. The main determinant of risk of  atherosclerosis from elevated 
VLDL and hypertriglyceridemia is by the level of cholesteryl esters 
enriched VLDL remnants. The atherogenic potential of IDL and VLDL 
remnants are the same. 
ASSOCIATION BETWEEN LIPOPROTEINS AND 
ATHEROSCLEROTIC HEART DISEASE 
HYPERCHOLESTEROLEMIA 
 The main factor that is clearly associated with increased risk of  
CAD is hypercholesterolemia. 70% of the cholesterol is found in LDL 
which is the primary target for intervention in the guidelines under 
NCEP. 
LDL 
 Low density lipoproteins also influences the CAD risk. LDL 
occurs in conjunction with increased TGL ,low  HDL , truncal obesity, 
and hypertension. The exact mechanism by which LDL causes 
atherogenesis is still unclear. In comparision with large LDL, the scialic 
acid content of small LDL is low which may cause increased binding 
capacity of LDL to proteoglycans in the arterial wall. When the density of 
LDL particles are increased it is found that  there is dose dependant 
increase in thromboxane synthesis. Also small LDL are more vulnerable 
to invitro oxidation when compared to large LDL. It has been evidenced 
that by lowering the LDL-C there is reduction in cardiovascular 
mortality. 
OXIDISED LDL  
 Due to the exposure to the endothelial cells, smooth muscle cells, 
macrophages the LDL gets oxidized. Due to this oxidation it attracts 
monocytes which is adhered to the arterial wall, and is prevented from 
dissociation with arterial wall scavenger receptors and so intracellular 
cholesterol accumulates. Due to the continuing uptake the macrophages 
are converted into lipid laden foam cells, which is the main culprit of 
atherosclerotic lesion. 
TRIGLYCERIDES 
 TG s are independent risk factor for coronary artery disease, so the 
remnant lipoproteins ( mixture of TG s and some lipoproteins) should be 
atherogenic. There is definite correlation between CAD and TG s. 
Triglycerides being atherogenic it causes various complications that are 
life threatening. Females have a definite risk factor for CAD with 
increased TG s.  Above 65 years 
1
 TG s are considered to be an important 
predictors of CAD. Many studies also suggested that in patients with type 
2 DM  there is definite positive association between CAD and number of 
triglycerides in plasma. 
HDL  
HDL possess  an inverse relationship with atherosclerotic cardiovascular 
disease. Also HDL is an antioxidant to LDL-C has it decreases the 
platelet aggregation. So that it is always mentioned as good cholesterol. 
As we all know HDL transports cholesterol from peripheral tissues to 
liver by the process termed reverse cholesterol transport, which reduces 
the oxidation modification of LDL, thereby it acts on endothelial cells 
and cytokine induced expression of adhesion molecules. A study on 
adenosinetriphosphate binding cassette(ATPC) proteinA1 transporter 
have finded a role of this transporter in liver and peripheral tissue 
2  
with 
the levels of  HDL and cholesterol. It is also founded that the persons 
with cardiovascular diseases has low levels of HDL-C 
3
. 
METABOLIC COMPLICATIONS OF HIV 
Insulin resistance, dyslipidemia , lipodystrophy, are commonly seen in 
adults with HIV infection and also is more pronounced in patients 
receiving HAART 
4
. These complications will increase the patients risk 
for cardiovascular complications and thereby increases the mortality, 
because of these metabolic complications the quality of life is very much 
questionable among them. 
 
DYSLIPIDEMIA IN HIV PATIENTS ON HAART 
 The association of dyslipidemia in the patients already started on 
HAART is of  a different pattern from patient going to be started on 
HAART. Mainly protease inhibitors and some of the non nucleoside 
reverse transcriptase inhibitors have been found to alter the lipid profile 
in such a  manner to be complicated with cardiovascular complications. It 
has been found that there is increase in total cholesterol, triglycerides, 
LDL-C, lipoprotein a
5
. Protease inhibitors and some of the NNRTIs 
inhibits a protein called sterol regulatory enhanced binding protein-1 
(SREBP I) which causes a increased lipid production by the liver 
6
. The 
other important factors that causes dyslipidemia are visceral fat 
accumulation, lipoatrophy, insulin resistance. 
 The main mechanism by which the NNRTI s induces lipoatrophy is 
by inhibition of SREBP1 that mediates activation of retinoid x receptor 
PPARY coactivator 1 
7
. 
 An important cross sectional study conducted by Friis moller et al 
reported that about 23% of patients who receives a NNRTI and 10% who 
receives only NRTI has elevated levels of cholesterol of about more than 
240 mgs when compared to only 8% of previously untreated patients. The 
same data for that of triglycerides of more than 200 mgs are 32% and 
23%  on comparision with only 15% among patients of previous subjects 
who have not yet started on ART, this makes a definite difference of 
dyslipidemia induced by HAART. 
 Also low levels of HDL of about less than 35 mgs were reported 
with 19 and 25% of subjects on treatment when compared to 26% those 
have not started on  ART. Framingham offspring cohort study found that 
some evidence for body fat abnormalities that 57% of individuals has 
elevated TG s more than 200 mgs and 46% of individuals with HDL of  
less than 35mg. 
 There was a prevalence rate of 57% among patients infected with 
HIV for cholesterol above 200 mg when compared to controls in 
Framingham study which is 42%. 
 By inhibition of mitochondrial DNA polymerase of adipocytes the 
nucleoside analogues cause lipoatrophy and dyslipidemia through 
mitochondrial injury. Efavirenz based regimens have been found to cause 
more dyslipidemias and cardiovascular risk factors when compared to 
nevirapine based regimens. The two mechanisms by which those drugs 
cause insulin resistance and hepatic steatosis are impaired fatty acid 
oxidation which causes intra myocellular fat accumulation, and increased 
circulating fatty acids. 
 
FAT ABNORMALITIES IN HUMAN BODY 
 It has been reported that about 40 to 50% of HIV infected patients 
have abnormalities in body fat composition and the above mentioned 
proportion is in higher level in patients receiving HAART 
8, 9 ,10
. There is 
wide variability in prevalence rates from 11 to 83% as mention in many 
cross sectional studies 
11, 12
. 
 Depending upon the charecteristics ( age, sex, race) , type  and 
duration of HAART and the population that we are comparing, the 
lipodystrophy rates may vary 
13
. There is no clear cut evidence of 
differentiation in definitions of loss of subcutaneous fat and gain in 
truncal fat. A study based on DEXA that is dual energy X ray 
absorptiometry and CT  was validated but still it is not recommended in 
our clinilal practice. 
There is subcutaneous lipoatrophy and accumulation of fat in HIV 
patients. Subcutaneous lipoatrophy is mainly noted in face, limbs 
buttocks and trunk 
13
. Visceral fat is mostly accumulated as central fat. 
There is variation in total abdominal fat accumulation and also it is 
independent of peripheral fat loss. The area that fat accumulates are 
breast, over dorso cervical spine, muscle and the liver. This pattern of fat 
distribution that is central lipohypertrophy will results in increased waist 
hip ratio (WHR). 
 Prospective studies that investigates total body fat composition in 
those who are going to be started on ART first time have found to have 
initial increase in fat in limbs during their first few months, which is then 
followed by progressive decline during the upcoming three years  
14
. But 
in contrast there is increase in truncal fat initially followed that there is a 
stable phase in ensuring two or three years that results in central 
adiposity. There are clinical evidence of changes in central and limb fat 
masses in about 20 to 35 % patients after starting HAART 
14
 
15
. 
PATHOGENESIS OF LIPODYSTROPHY 
 There is a change in body fat composition in patients who have not 
received HAART but it has been observed that maximum changes will 
occur after starting HAART. 
 It also been founded that the syndrome is less likely to be caused 
by direct effect of HIV. It is exclusive to those who received HAART. 
Also there is improvement in both lipoatrophy and visceral fat 
accumulation after reverse transcriptor switch over without any changes 
in viral load 
16
. Also many studies have found that there is no or negative 
association between increasing HIV RNA and lipodystrophy. 
 The strong association with severity of lipoatrophy is mainly by 
type, duration and use or nonuse of HAART particularly in a combination 
between two NRTI and a PI s which both of them have a strong 
association with lipoatrophy 
17
. So that these main two ARTS are 
concerned with cardiovascular complications and thereby increases the 
morbidity and mortality.  
 NNRTIs will induce lipoatrophy by inhibiting SREBP1 mediated 
activation of adipocyte retinoid x receptor and peroxisome proliferators 
activared receptor gamma (PPAR gamma) or by PPAR gamma 
coactivators 1 
18, 19
.  
 The nucleoside analogue that is strongly associated with 
lipoatrophy is stavudine especially when used with didanosine 
20, 21
. The 
mechanism by which the nucleoside analogues causes lipoatrophy is due 
to mitochondrial injury that results from inhibition of mitochondrial 
polymerase gamma within the adipocytes 
22
, and also by depletion of 
mitochondrial DNA 
23
. Also the nucleoside analogues will inhibit the 
adipogenesis and adipocyte differentiation 
24
. The factors that are 
associated with lipoatrophy are old age, lower body weight, prior to the 
diagnosis of  AIDS and a lower CD4 count. Womens have more central 
fat accumulation than men 
25
. Increased fatty acid storage and impaired 
fatty acid oxidation or both of them will result in increased intracellular 
lipid contents, hepatic steatosis and insulin resistance 
26, 27, 28
. 
          Generalised wasting will occur in HIV other than lipodystrophy. 
An AIDS defining condition is generalized wasting. It is defined as more 
than 10% involuntary weight loss in association with intermittent or 
constant fever, fatiguability and chronic diarrrhoea that lasts for more 
than 30 days in the absence of a defined cause other than HIV infection. 
The most consistent feature of this syndrome is severe muscle wasting 
with myofibre degeneration and occasionally myositis 
29
. 
INSULIN RESISTANCE AND ABNORMAL GLUCOSE 
HOMEOSTASIS 
 A surrogate marker for insulin resistance that is hyperinsulinemia 
is most commonly seen in patients having increased truncal fat, decreased 
fat in limbs, increased waist hip ratio, and a buffalo hump 
30
. As by Carr 
et al 
31
 who matched for age and body mass index with that of  HIV 
infected individuals having lipoatrophy or fat accumulation the diabetes 
mellitus was seen in 7 % of individuals when compared  with healthy 
controls. Also the impaired glucose tolerance was seen in 35% of HIV 
infected subjects in comparison with just only 5% with healthy controls. 
In some other longitudinal study it was observed that the development of 
diabetes mellitus in HIV patients receiving combination HAART  over a 
3 year period of observation was found to be 3.1 times when compared to 
those who are not receiving. The rate at which  both the above mentioned 
categories that progress to overt diabetes is not known. 
PATHOGENESIS 
 ART will leads to increased free fatty acid production, 
intramyocellular fat accumulation, adipokine level alteration and a 
decreased PPAR gamma expression with a  altered glucose 
homeostasis
32
. Various ART s also found to cause insulin resistance 
invitro by decreasing the glucose transport which was mediated by GLUT 
4 transporter
33
. Insulin sensitivity is affected by change in body 
composition
34, 35
. Nucleoside analogues will cause insulin resistance 
through changes in fat distribution. 
CLINICAL CONSEQUENCES 
 As we already seen that the metabolic complications such as 
dyslipidemia, insulin resistance, loss of subcutaneous fat and increase in 
central fat are commonly seen in patients infected with HIV. These 
complications increase the risk of both cardio and cerebrovascular 
complications. The other main risk associated with increased TG levels is 
pancreatitis. The pancreatitis which results from the effect of  
triglyceridemia will  result in acute abdomen, vomiting, faintness, severe 
dehydration, and can lead to death. 
CARDIOVASCULAR DISEASE  
 After the introduction of protease inhibitors and non nucleoside 
reverse transcriptase inhibitors for HIV infection, it was observed to have  
many unexpected cardiovascular complications with the  patients 
receiving ART, eventhough the patient undergoes many and many 
complications induced by the disease itself, in addition the drugs induced 
for cessation of disease progression may also induces several 
complications. The young people receiving this HAART also can  met 
with angina, MI, stroke and also sometimes peripheral vascular disease. 
There is also confusion among clinicians that these complications are 
either due to chronic HIV infection itself or due to new anti HIV 
regimens. 
 Another study conducted from Kaiser permanente medical care 
programme from northern California founded that the HIV patients 
regardless of the use of HAART therapy was hospitalized for 
cardiovascular and cerebrovascular complications of about 1.5 times than 
that of uninfected counterparts  
36
. 
 Another data was collected from more than 24,400 patients from 
Europe, United states and Australia conducted by Friis moller and 
collaborators on adverse effects of  HAART. From this study it was 
found that over a median period of 1.6 years about 126 patients had 
myocardial infarction. Also on analyzing  the duration of drug exposure  
they came to know that in the first 4 to 6 years of combination therapy, 
there was about 16% relative increase in rate of MI per year. 
  DAD study group reported about 346 deaths that are due to 
cardiovascular events with a confirmed incidence of 3.45% in 
comparision to 1.4% in controls. There is inevitable increase in risk of 
cardiovascular disease among HIV patients due to their pre existing 
burdens of traditional risk factors such as old age, smoking, 
hypercholesterolemia, DM, male sex, previous history  of  MI 
37
. Not all 
but some of cardiovascular risks may be due to effect of HIV infection or 
due to ART or due to combined effect of all of  them, whatever may be 
the effect, the patient are caught hold of  numerous complications that are 
especially dealt with the cardiovascular system.  
MECHANISM 
Like other infectious agents such as cytomegalovirus, herpes 
simplex, and Chlamydia,  HIV infection itself will cause atherosclerosis 
on endothelial cells through proinflammatory effect, that causes various 
complications. It causes cardiovascular instability either directly or due to 
various drugs. On getting HIV infection there is reduction in HDL 
cholesterol level. 
The disease progression and HIV viremia is strongly associated 
with hypertriglyceridemia 
38
. When compared to uninfected controls the 
infected persons at the median age of 45 years it is noted that there is 
increased carotid intimal thickness and increased rate of disease  
progression. The risk factors such as hypertension, hypercholesterolemia, 
smoking, diabetis mellitus, alcoholism, are strongly associated increased 
carotid intimal thickness. In electron beam computed tomography, it is 
found to have coronary artery calcifications in HIV patients, the 
fibrinolysis is impaired in HIV patients in terms of increased tissue 
plasminogen activator and plasminogen activator inhibitor 1. 
The ART will further increase atherosclerosis either directly or 
indirectly. The two main mechanisms are endothelial dysfunction and 
decreased flow mediated dilatation seen in patients receiving protease 
inhibitors 
39
. The patients receiving ART have increased risk of 
developing hypertension than who have not, also it is associated with 
increased body mass index. The main aim is to detect the metabolic 
abnormalities attributed by ARTs which indirectly causes atherosclerosis.  
Another important mechanism is by increasing the CD 36 dependant 
cholesterol ester in macrophages the protease inhibitors  will promote 
atherosclerosis 
40
.  
In addition some ARTs are associated with insulin resistance. 
Patients on ARTs have lipodistrophy which will itself causes 
atherosclerosis, so the HIV treated patients will have lipodystrophy, 
diabetes, elevated lipoproteins which have the toxic effects on 
endothelium. So in nutshell the patients started on ART have a greater 
risk of development of atherosclerosis. 
The exact mechanism of  vascular events in HIV infected patients 
are not clearly known, but may be related to DM, dyslipidemia, insulin 
resistance, inflammation, impaired fibrinolysys, factor related to ARTs or 
combination  of above factors. 
ASSOCIATION WITH PANCREATITS   
The increased triglycerides levels seen in HIV patients or patients 
receiving HAART has found to have serious pancreatitis but this is not 
reported in literature. 
METABOLIC AND BODY FAT ABNORMALITIES 
ASSESSMENT 
DYSLIPIDEMIA 
In every HIV patients fasting lipid profile have to be measured 
before initiating  ART and also after changing ART regimen , in addition  
the family history of dyslipidemia, DM, alcohol intake, or any other 
medications intake is to be determined. The possible ART which worsens 
the lipid levels should selected for patients with dyslipidemia. 
GLUCOSE HOMEOSTATIC ABNORMALITY 
Fasting glucose levels should be measured before starting ART and 
should be then measured annually, as well as when there is a change in 
ART. Weight and any family history of diabetes also should be assessed. 
There will be definite impaired glucose tolerance and insulin resistance in 
those patients before the development of overt diabetes. 
Hyperinsulinemia and impaired glucose tolerance are the two 
major risk factors for cardiovascular complications. So a fasting glucose 
or oral GTT should be performed in patients with HIV started on ART. 
ABNORMALITIES IN BODY FAT 
It should be mandatory to have annual assessment of body fat for 
the patients to be started on HAART, especially on protease inhibitors or 
NRTIs or NNRTIs  as well as to patients  who are going to be switched 
over to other ARTs. Dual energy Xray absorptiometry is used for 
measuring fat in the limbs. Also the additional information are provided 
by measuring the truncal and limb fat, WHR measurement, thigh 
circumference. CT scan gives us extra information about visceral and 
abdominal fat. Due to the risk of radiation exposure it should not be used 
clinically. For assessing facial lipoatrophy no techniques has been 
validated.  
MODIFICATION OF RISK FACTORS 
All risk factors that includes dyslipidemia, insulin resistance, 
hypertension, smoking, alcohol intake, sedentary life style, family history 
should be assessed carefully. The first recommendation that includes are 
lifestyle modification and dietary alterations, interventions for smoking 
and hypertension, subsequently the lipid lowering therapies or a change 
in ART should be considered. The measures for DM and insulin 
resistance includes initiation of insulin sensitizing agents. The 
modification should be in such a manner that it should balance both the 
risk of cardiovascular events and risk of progression of HIV disease to 
that of  long term use of retroviral therapy , eventhough there is increased 
risk of cardiovascular disease in HIV patients, it is almost low to 
outweigh the benefits from aministering ARTs. For the patients with 
advanced disease or HIV patients who are resistant to ART the risk of 
cardiovascular complications are a lesser concern. So when we are 
planning to initiate ART it should be kept in mind  that the ART which 
we are going to start should  have a  lower propensity to elevate lipid or 
glucose levels. 
 
ANTILIPEDEMIC DRUGS 
To treat isolated hypercholesterolemia statins are used and for 
isolated hypertriglyceredemia fibrates are used. Both the statins and 
fibrates can also be tried if the response is incomplete provided there 
should be careful monitoring of creatine kinase and aminotransferase 
levels 
41, 42, 43
. Usually the guidelines provided by NCEP should be 
followed when initiating lipid lowering therapy in HIV infected patients 
until other specific recommendations are available. Drug interactions 
between lipid lowering agents and ARTs should be always kept in 
mind
44
. 
INSULIN SENSITISORS 
Metformin which is a insulin sensitisor have been found to 
improve insulin sensitivity and decrease the visceral adiposity, reduces 
tissue plasminogen activator and plasminogen activator inhiobitor 1, and 
also the BP. Another molecule ROSIGLITAZONE is used in patients 
with insulin resistance. 
GROWTH HORMONE 
Usually the growth hormone levels are low in patients with HIV 
infection especially who have excess visceral adiposity and in those 
patients growth hormone secretogogues can be tried to restore the body 
fat to normal back  
45,46,47,48
. 
ROLE OF SURGERY 
For facial lipoatrophy various injectable agents are tried. A 
reabsorbable molecule polylactic acid is used widely which promotes 
collagen formation and it improves facial soft tissue appearance. 
Liposuction can be tried on patients especially with dorsocervical fat. 
SWITCHING OVER TO OTHER REGIMENS 
Cessation of zidovudine can generally lead to improvement in limb 
fat. Replacement of drug for the other which has the low potential to 
increase the above mentioned complications can be tried 
49,50,51,52
. 
However the cessation of drugs alone cannot improve the lipoatrophy. 
 
 
  
MATERIALS AND METHODS 
 
Setting:      HIV patients of age from 18 to 60 years who were 
attending ART   Centre, Coimbatore medical college hospital, and 
patients admitted in  Medical and STD wards at  CMCH- CBE.  
Collaborating Department:   Antiretroviral therapy centre,                 
CMCH – CBE,  Biochemistry department, CMCH 
Design of  study  :     Observational study. 
Period of study  :      1 year. 
Sample size        :      100 
Ethical committee approval  :   obtained 
Consent           :   informed consent obtained 
Financial support    :   nil 
Conflict of interest    :   nil 
 
  
METHODOLOGY 
STUDY DESIGN  :  observational study 
PATIENT SELECTION  : 100  diagnosed HIV patients in Coimbatore 
medical college hospital was selected and the study was conducted  
during the year 2013-14 which includes 50 patients started on HAART 
and 50 patients not started on HAART. 
INCLUSION CRITERIA  : 
•  HIV patients attending the ART centre 
• Age group of both sexes 18 to 60 years 
• Patient with good adherence to HAART 
EXCLUSION CRITERIA  : 
• Diabetes 
• Hypertension 
• Coronary artery disease 
• Chronic renal failure 
• Already diagnosed dyslipidemic patients 
• Obesity ( BMI > 25 ) 
 
 
TECHNIQUES :  
HISTORY AND EXAMINATION : 
Patients  included in the study were divided into five groups 
Group 1 : patients on ZDV+3TC+NVP (no of patients : 12) 
Group 2 : patients on ZDV+3TC+EFV (no of patients : 14) 
Group 3 : patients on TEN+3TC+NVP (no of patients : 6 ) 
Group 4 : patients on TEN+3TC+EFV (no of patients : 18) 
Group 5 : patients not started on HAART. 
A proforma containing details for every patient that includes age, 
relevant history of smoking, alcoholism, marital status, history of TB. 
The height was measured barefoot in meters and weight in kilograms 
in a normal indoor clothing. Waist circumference was measured in 
terms of narrowest measurement in between ribcage and the iliac 
crest, vital signs were recorded and clinical examination of all the 
systems were made. 
FASTING LIPID PROFILE MEASUREMENTS 
        The patients venous blood samples will be taken to measure the 
serum lipid profile levels with 12 hours overnight fasting  for both the  
groups. Fasting lipid profile levels will be measured. Lipid profiles 
will be repeated  at 6 months and one year. The lipid profile estimation 
was done in ERBA – XL 300 automatic analyser.  
STATISTICAL METHODS : 
 The Statistical analysis was performed using SPSS version 19.0 . 
Normal data was measured using mean and standard deviation . To 
correlate various clinical variables pearson correlation co-efficient 
with single tail analysis was done.  
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About 100 patients was selected in the study, they were divided into 5 
groups.  The first group was on ZDV+3TC+NVP, this group has about 12 
members, the second group was on ZDV+3TC+EFV which has 14 
members, then the third group on TEN+3TC+NVP with 6 members, the 
fourth group of TEN+3TC+EFV with 18 members, then the final fifth 
group of non HAART with 50 members. In the patients on HAART 
group maximum number of patients falls into group 4 which was on 
TEN+3TC+EFV with 36%, the least number of patients falls into group 3 
those who are on TEN+3TC+NVP of about 12%. 
        In coimbatore medical college hospital we are using only first line 
regimen that includes Zidovudine, Lamivudine, Efavirenz, Nevirapine, 
Tenofovir. 
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The age wise distribution among HAART patients at the age 18
about 14, the patients  in the age group between 36
51-60 are 9, the patients in 
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The number of males in the goup 1 to 4 are 7, 8, 3, 10 respectively and  
the number of  females 
HAART are about 29 males and 21 females.
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TABLE : 11 MARITAL STATUS OF THE PATIENTS 
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CHART : 4  MARITAL  STATUS
 
The number of patients in the HAART
41    and the unmarried patients are 9, the number of married patients in 
the non  HAART are 42 and the unmarried patients are 8, with 82% ,
18%,84%,16%  respectively.
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SMOKER 
NON SMOKER
 
 
The patients who are smoking in HAART group are 16 with 32%, and the 
non  smokers are 34 with 68%, the patients in the non HAART who are 
smoking are 21  with 42% and those who are no
58% . 
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The number of alcoholics and non alcoholics in the HAART group were 
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The number of  patients were divided into  groups in such a way that the 
patients in the non 
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CHART : 7 PREVALENCE OF TB
 
Since the prevalence of TB is very common in HIV patients it is 
important to describe its distribution. The patients in non HAART group 
has no TB, whereas the patients in HAART group infected with TB are 
30 in number and the patients without TB are 20. 
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COMPARISON OF LIPID VALUES
TABLE: 15 TOTAL CHOLESTEROL FOR THE 0 MONTH
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The mean value for total cholesterol for the patients on  non ART and  
ART  at the 0 month are 163.94 and 165.22, which has the p value  of 
0.196 which was not significant 
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The same mean at 12 months are 175.24 and 214.24 respectively 
with a p value significance of 0.000.
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CHART: 13 TRIGLYCERIDE FOR    12 MONTH
Similarly the mean values for triglycerides for non ART 
6, 12  months are 124.78 and 128.62, 133.94 and 152.08, 145.90 and 
159.98 respectively 
p values of  0.007, 0.000, 
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The LDL cholesterol for the
mean values at 0, 6, 12 months are  98.74 and 106.2, 114.46 and 132.26, 
123.84 and 143.58 respectively, they are statistically  significant with the 
p values with 0.002, 0.000 and 0.000.
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CHART: 19 HDL FOR  12 MONTHS
 
The mean values for the HDL cholesterol similarly for the non ART and  
ART  patients for the 0, 6, and 12 months are 43.46 and 40.42, 40.44 and 
38.10, 39.32  and 39.30 respectively with  a 
0.960 
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As the groups included in the ART are mainly based on Efavirenz and 
Nevirapine,   and many studies have been dealt upon those two drugs, the 
comparison is done 
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cholesterol values between these two  drugs are 240.43 and 220.20 which 
has a statistical  significance p value of 0.000, the TGL mean values are 
174.43 and 172.40 which was statistically insignificant with a p value of 
0.586, where as the mean values of LDL between these two groups were 
158.68 and 155.20 respectively which has a statistically significant p 
value of 0.036, finally the comparison between  these two for HDL level 
has the mean value of 35.37 and 36.00 with a p value of 0.328 which was 
statistically insignificant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
DISCUSSION AND COMPARATIVE ANALYSIS 
               HIV as mentioned earlier is a retrovirus belonging to a 
subfamily of lentivirus. AIDS was first identified in united states in the 
year 1981. According to NACO the AIDS prevalence in India was 0.27 in 
the year 2013which was decreased  from 0.41 in the year 2002. Since the 
last decade there has been a 50% decline. Also according to our NACO 
status  India has faced a 57% reduction in annual new infections from 
0.274 million in 2000 to 0.116 million in 2011. And also there is a 
decline in AIDS related deaths of  29%  between 2007 and 2011. 
        First case of AIDS in India was reported in the year 1986 about 2.4 
million peoples are living with this condition and about  1, 70,000 
HIV/AIDS related deaths were happened. 
        The introduction of  HAART for the sake of HIV patients had 
enlighten their life by the means of dramatic reduction in HIV related 
deaths and morbidity in each and every countries. A very strict adherence 
to ART will prevent the viral replication and also the effects of the 
disease .  Because of the introduction of the HAART  the quality of life of 
the patients was definitely improved . Even though there was a drastic 
change in the quality of  life of the  HIV patients, there occured  
comorbid problems such as dyslipidemia, insulin resistance and diabetes 
with the long term use of HAART. 
           The study was conducted in Coimbatore Medical college hospital 
ART department for the adult patients who are  at the age group of 18 to 
60 years. According to this study the maximum number of patients was 
between 36 – 50 years. Also many other studies has showed the 
maximum number of patients who are affected were in these age groups.  
The age distribution showed a maximum prevalence in the age group of 
36 to 50 years. 
          Coming to the sex distribution among the patients the number of 
male patients in the group 1 was 7 and the number of female patients was 
5 with 14 and 10% respectively ,  with the group 2  it was 8 and 6 for 
males and females with 16 and 12 %. And with that of group 3 it was 
both 3 for males and females that constitutes about 6% each. It was 10 
and 8 for the group 4 with the correspondence of 20 and 16%. Group 5 
constitutes 29 males and 21 females with 58 and 42%. 
         In our study we have also done a marital status distribution even 
though it is going to be insignificant to this study, it was about 41 ART 
and 42 non ART are married with 82 and 84% of distribution. 
         Also the smoking habits were studied in the patients that the number 
of patients who are smokers among ART patients are 16 and to that of 
non ART are 21 whom are all males. According to a national survey 
conducted in India the percentage of smokers in India was seems to be 
23%  in the year 2012. Since smoking is a confounding variable the 
analysis was adjusted according to that.  
        Prevalence of alcohol in our study group  are 8 persons in the 
HAART are alcoholics and  42 persons are non alcoholics which are 16% 
and 84%. In non HAART group the alcoholics are  12 in number whereas 
38 are non alcoholics which are 24 and 76% respectively. 
        With the CD4 count all patients in the non HAART groups had the 
count of more than 350, the patients in the HAART group are divided 
into four groups, the first group which contains 8 patients has CD4 of less 
than 50, the second group with 17 patients has CD4 between 50-200, the 
third group with 10 patients has CD4 between 200-350, and the fourth 
group with 15 patients has CD4 count of more than 350. 
       Since the prevalence of TB in our country is wide spread its 
distribution with HIV patients are assessed. The patients with HIV had 
two groups with TB and the second one without TB. The first group has 
30 patients and the second one has 20 patients, whereas the patients on 
non ART has no TB. 
      According to NCEP – ATP criteria the dyslipidemia is defined as TC 
of more than 200mg/dl, TGL of more than 150mg/dl, LDL of more 
than130mg/dl, HDL of less than 40mg/dl. In the present study according 
to the definition there should be atleast one lipid abnormality  to brand as 
dyslipidemia. 
       In our study the patients in the both groups have a baseline normal 
lipid values, finally in the patients who are started on ART there was 26 
lipid abnormalities which constitutes about 52% of the total value. Of 
which the Efavirenz based regimen has 16 persons with lipid 
abnormalities whereas the patients on Nevirapine based therapy has a 
lipid value abnormality of 10 persons which both constitutes 32 and 20% 
respectively. 
     According to a study conducted by Agete Tadewos et al, Zalalem 
Addis, Henock Ambachew and Sandip banerjee et alwhere 226 patients 
were involved out of which 113 were ART patients and 113 were non 
ART patients. In the above mentioned study 93% of the patients on 
HAART that is 82.3% had at least one lipid abnormality, in our study 
about 52% of the patients has significant lipid abnormality, in the above 
study conducted in Ethiopia the TC level of more than 200mg occurred in 
43% of the HAART, HDL below 40 mg occurred in 44%, the low density 
lipoprotein elevation occurred in 34%, and the increased TGL level seen 
in 55% of the patients, comparatively in our study  with  one  year 
observation we have 27 patients with elevated total cholesterol level 
which constitutes 54%, and about 25 patients have elevated triglyceride 
level with 50%, whereas the LDL level was increased in 52% of the 
patients , finally the HDL level was decreased almost in every patients. 
       The mean value for the total cholesterol in the Ethiopian study group 
were 234.76 mgs, whereas in our study the mean value at one year was 
observed as 214.24mgs, following which the mean value for triglycerides 
in the Ethiopian group was 161.23mgs compared to a mean value of 
159.98mgs in our study. When coming to the LDL level the African study 
has the mean value of 138mgs compared to our  study which has 
143.58mgs, finally to the HDL the Africans has mean value of 38.23 
comparing to our study of 39.3 mgs. 
 In our study the association of  TC  between ART and non ART is 
not statistically significant at 0 month which has a p value of 0.196, 
whereas the association of the same at 6 and 12 months are statistically 
significant with a p value of 0.000, comparatively the  TGL values 
association with ART and non ART are statistically significant with a p 
value of 0.007 and a p value of 0.000. Also the significant association  is 
seen with  LDL  for ART and non ART groups which has the p value of 
0.002 and 0.000. whereas there is a  statistical significant association  for  
HDL  seen at  0 and 6 months with  a  p value of 0.000, and at one year it 
was 0.960 which was statistically insignificant. 
      As in our study where the HDL values are statistically insignificant 
with a p value of >0.05 at the end of one year, another study conducted at 
Nigeria by Francis M.Awah et al and Onyine Agughasi et al with 50 
patients that 25 on ART and 25 not on ART  also has the same outcome 
in which there was statitically significant p value association  seen with 
that of TC, TGL, LDL but not with  that of HDL where there was a 
statistical insignificance with a p value of >0.05. 
       Since we are discussing about many studies conducted in various 
countries it is also very important to know about the studies done in india. 
A study  was conducted by RAB Carey,  P Rupali,  OC Abraham,  D 
Kattula at Christian medical College,  Vellore  regarding the  prevalence 
of cardiovascular risk  factors  in Indian  patients using first line ART, it 
showed 
 HIV pts on ART HIV pts not on ART 
TC 195.60 151.47 
TGL 268.34 121.57 
HDL 42.38 32.55 
LDL 106.36 93.24 
 It was discussed from this study that there are limited data from the 
developing countries like India where most of the patients was on first 
line ART, from this study it was found that there was an increased 
prevalence of dyslipidemia in the patients who are in first line 
antiretroviral therapy. 
          Since many studies that was conducted in developed countries are 
mainly with that of protease inhibitors, the above mentioned study was 
dealt with first line ART that too with NRIs and NNRIs. 
         In this study there was high prevalence of hypercholesterolemia and 
hypertriglyceredemia and there was a low prevalence for low HDL, 
comparatively in our study also there was high prevalence of 
hypercholesterolemia and hypertriglyceredemia and also in addition there 
was high prevalence of low HDL. 
        By these data it is clear that due to prevalence of dyslipidemia there 
will be a definite increase risk in cardio and cerebrovascular 
complications among our Indian population. 
       In comparison for the Efavirenz  and  Nevirapine the lipid profile 
derangements were extensively studied. In the studies conducted by 
Frank van leth et al, Prahpanphanuphak et al the lipid derangements with 
that of efavirenz was very much increased compared to nevirapine. The 
total cholesterol and triglycerides were increased by efavirenz whereas 
HDL was increased by nevirapine . In our study there was a statistically 
significant difference in total cholesterol values  at one year with  a  p 
value of 0.000 even though both  the drugs increased the total cholesterol 
value, regarding the LDL value also there occurs a significant association 
with the p value of <0.05 even though both  the drugs had increased the 
LDL values, but in comparison of HDL value to that of the study our 
study tend to decrease the HDL values with the usage of these two drugs. 
 Another study done by Jane A o Halloran et al, Claudette S 
Satchell and Patrick mallon et al   found that there is significant rise in 
TC and TGL values when the patients are started with efavirenz when 
compared to nevirapine. 
 Coming to the zidovudine and tenofovir we have not  compared the 
actual lipid derangements between these two groups, but there were 
studies showing that tenofovir tends to increase a little bit rise in total 
cholesterol and low density lipoprotein in comparison with that of  
zidovudine. This was studied by  Gallant JE, Dejesus E and Arribas JR et 
al, but in contrast to this study many studies founded that tenofovir has a 
favourable lipidprofile compared to that of zidovudine. In  the study done 
in  Hawassa , southern Ethiopia the lipid profile derangements between 
these two drugs were as follows 
LIPID 
PROFILE 
 
ZDV BASED 
n = 58 (%) 
TEN BASED 
n = 55 (%) 
P value 
TC> 200 mg 25 (43.1) 24 (43.6) 0.95 
HDL< 40 mg 24 (41.4) 25 (45.4) 0.66 
LDL> 130 mg 20 (34.5) 18 (32.7) 0.84 
TGL > 150 mg 32 (55.2) 31 (56.4) 0.41 
 
So in this study when compared to previous study the lipid abnormalities 
are almost equal with a slight upper hand with that of zidovudine , but 
however there is no significant difference in lipid abnormalities between 
these two. 
 The same study groups at Hawassa, Southern Ethiopia was 
compared for nevirapine and efavirenz which the results came as follows 
 
LIPID PROFILE 
 
EFV BASED 
n = 46 (%) 
NVP BASED 
n = 67 (%) 
TC> 200 mg 18 ( 39.1) 31  (46.3) 
HDL< 40 mg 22 (47.8) 27 (40.3) 
LDL> 130 mg 14 (30.4) 24 (35.8) 
TGL > 150 mg 25 (54.3) 38 (56.7) 
  In the above study even though the study group of the nevirapine group 
was one third more  than that of efavirenz there is no significant 
difference in abnormality in lipid parameters in between these groups. In 
the study done in our hospital,  the comparison between efavirenz and 
nevirapine is as follows, the TC for  efavirenz at 1 year study has a mean 
value of 240.4 and 220.2 for nevirapine with a statistical significant 
association of  0.000, similarly the mean value for TGL for both of these 
drugs are 174.43 and 172.40 which has no association with a p value of 
0.586, the same mean for LDL at the 1 year has the mean value of 158.68 
and 155.20 with a significant p value of 0.036, finally the mean  value of 
HDL  between  these  two  drugs was of  35.37 and 36.00 with no 
significant association with a p value of 0.328 . 
        EFV NVP p value 
     TC       240.43           220.20      0.000 
    TGL      174.43      172.4      0.586 
   LDL      155.20      155.2      0.036 
   HDL      35.37      36.00      0.328 
 
CONCLUSION 
1.  As observed by the study there are significant lipid abnormalities 
in patients on HAART. 
2. There  is a statistically  significant increase in  total cholesterol, 
triglycerides, low density lipoproteins among the HAART patients 
at the end of one year. 
3. However there is statistically insignificant decrease in high density 
lipoproteins in HIV infected patients on HAART. 
4. In comparison with efavirenz and nevirapine there is a statistical 
significant difference between these two with a increased incidence 
of dyslipidemia in efavirenz based regimen. 
5. Protease inhibitors which causes more lipid abnormalities than 
NRTIs and NNRTIs was not included, because it comes under 
second line regimen which is not used in our institution. 
 
            
  
 
 
 
SUMMARY 
 The main aim of this study is to determine the prevalence of 
dyslipidemia among the HIV patients using first line HAART. Since 
many studies has found that  the incidence and prevalence of 
dyslipidemia among HAART users are increasing it is very important to 
find our patients living in and around our city living with dyslipidemia. 
By finding the lipid abnormalities we can try to decrease the incidence of 
cardiovascular and cerebrevascular complications. 
 Out of 100 patients included in our study , we compared  50 
patients were already  on HAART and 50 patients not yet started on 
HAAR. The ART regimen was initiated according to the WHO 
guidelines. The patients who were exposed to HAART for a minimum of  
2 years were selected in our treatment group.  They were distributed 
according to their age, sex, marital status, CD4 count , smoking and 
alcohol habits and prevalence of TB. 
             From the results obtained in our study it is clear that the 
prevalence of dyslipidemia( elevated TC, TGL and LDL) was higher in 
patients on ART when compared to patients not on ART                                
(p value < 0.001). There was no difference in the prevalence of HDL. 
Even though both efavirenz and nevirapine had an impact over lipid 
profile,  the prevalence of dyslipidemia was more with efavirenz.   
         In conclusion by monitoring the lipid parameters in  HIV patients  
to be started on HAART, we can   start them  with lipid friendly drugs if 
there is associated dyslipidemia, on the other hand the patients with 
dyslipidemia who was already on HAART can be switched over to lipid 
friendly regimens or we can add lipid lowering drugs . So by doing this 
we can at least  prevent or reduce cardio and cerebrovascular 
complications and thereby we can improve the quality of life in patients 
who are already immunocompromised. 
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DEPARTMENT OF GENERAL MEDICINE 
Coimbatore Medical College, Coimbatore 
Principal investigator                      : Dr. Karthikeyan .N 
Research guide                                : Dr. M.Raveendran M.D.  
Organization                                    : Department of General Medicine  
Informed consent : I have been invited to participate in research Project 
titled ‘PREVALENCE OF DYSLIPIDEMIA AMONG HIV 
INFECTED PATIENTS USING FIRST LINE HAART IN 
COIMBATORE MEDICAL COLLEGE HOSPITAL’  
I understand, it will be answering a set of questionnaire, undergo physical 
examination, investigations and appropriate treatment.  
I also give consent to utilize my personal details for study purpose and 
can be contacted if necessary.  
I am aware that I have the right to withdraw at any time which will not 
affect my medical care.  
Name of the participant: 
Signature: 
Date  
  
xg;g[jy; gotk;; [ ; ;; [ ; ;; [ ; ; 
 
bgah;  : 
ghypdk; : 
Kfthp :     taJ  : 
  
muR nfhit kUj;Jtf; fy;Y}hpapy; bghJ kUj;Jt Jiwapy;  gl;l 
nkw;gog;g[ gapYk; khzth; kU.eh. fhh;j;jpnfad;; ; ;; ; ;; ; ; mth;fs; 
nkw;bfhs;Sk;  "nfhaKj;J}h; kUj;J; ; ;; ; ;; ; ; t fy;Y}hp kUj;Jtkidapy;             ; ; ;; ; ;; ; ;
vr; I tp  nehapdhy; ghjpf;fg;gl;l nehahspfSf;F Kjy; epiy ; ; ; ; ; ; ;; ; ; ; ; ; ;; ; ; ; ; ; ; ART  
kUe;J bfhLg;gjpdhy; ,uj;jj;jpy; cs;s  bfhGg;gpd; mstpy; Vw;gLk; ; ; ; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ; ; ;
khWjy; gw;wpa; ;; ;; ;  " Ma;tpy; bra;Kiw kw;Wk; midj;J tptu';fisa[k; 
nfl;Lf; bfhz;L vdJ re;njf';fis bjspt[gLj;jpf; bfhz;nld; 
vd;gij bjhptpj;Jf; bfhs;fpnwd;. 
ehd; ,e;j Ma;tpy; KG rk;kjj;Jld;/ Ra rpe;jida[lDk; 
fye;J bfhs;s rk;kjpf;fpnwd;. 
,e;j Ma;tpy; vd;Dila midj;J tpgu';fs; 
ghJfhf;fg;gLtJld; ,jd; Kot[fs; Ma;tpjHpy; btspaplg;gLtjpy;  
Ml;nrgid ,y;iy vd;gij bjhptpj;Jf;bfhs;fpnwd;. ve;j neuj;jpy; 
me;j Ma;tpypUe;J ehd; tpyfpf; bfhs;s vdf;F chpik cz;L 
vd;gija[k; mwpntd;.  
 
,lk; :                     ifbahg;gk; / nuif 
ehs; : 
  
PROFORMA 
 
Name       :CD4 count     : 
Age            : 
Sex             : 
IP NO        : 
BMI          : 
Marital status                   : 
Smoking habits   : 
History of Diabetes  : 
Hypertension     : 
CAD     : 
CRF     : 
Dyslipidemia          : 
Tuberculosis          : 
Alcoholism          : 
 
Treatment groups : 
Group I      - 
Group II      - 
Group III     - 
Group IV     - 
Group V      - 
LIPID PROFILE : 
 HAART 
GROUP 
  NON-
HAART 
GROUP 
  
 O M 6 M 12 M O M 6 M 12 M 
TC       
TGL       
LDL       
HDL       
 
  
KEY TO MASTER CHART 
1. 1 - Z L N     
2. 2 - Z L E  
3.  3 - T L N 
4. 4 - T L E 
5. 5 - NON – A R T 
6. UM  -  Unmarried 
7. M  - Married 
8. S  - Smoker 
9. NS  -  Non Smoker  
10. A  - Alcoholic 
11. B  - Non Alcoholic 
12. C  - CD 4 more than 350 
13. Y  - Yes 
14. N  - No 
 
 
S.No AGE SEX GRP MARR  SMOKE ALCOH CD4  TB 
TC TGL LDL HDL 
0 
MO 
6 
MO 
12 
MO 
0 
MO 
6 
MO 
12 
MO 
0 
MO 
6 
MO 
12 
MO 
0 
MO 
6 
MO 
12 
MO 
1 20 M 5 UM NS B C N 161 170 174 125 132 155 100 110 125 44 41 37 
2 23 M 5 UM S A C N 164 165 172 123 135 136 110 112 124 43 40 38 
3 33 F 5 M NS B C N 168 168 175 134 136 149 102 114 122 45 41 39 
4 34 F 5 M NS B C N 160 171 189 114 138 145 102 117 128 46 40 41 
5 45 M 5 M S B C N 163 169 165 135 146 156 107 118 127 41 40 38 
6 31 M 5 M NS A C N 165 170 178 116 126 170 106 131 126 47 40 42 
7 30 M 5 UM S B C N 168 198 172 117 156 143 104 101 124 40 42 39 
8 26 F 5 M NS B C N 166 165 186 134 116 141 102 128 121 42 41 38 
9 23 F 5 UM NS B C N 165 170 175 125 131 142 100 99 122 43 40 41 
10 28 F 5 UM NS B C N 169 171 179 126 137 143 92 110 125 44 42 42 
11 35 M 5 M S A C N 160 174 165 128 130 159 112 114 122 46 40 39 
12 35 M 5 M NS B C N 162 175 185 130 131 141 101 118 124 44 41 44 
13 31 F 5 M NS B C N 163 187 176 123 132 134 89 117 124 41 40 36 
14 44 M 5 M S A C N 166 170 186 123 131 168 101 114 124 42 40 35 
15 30 M 5 M NS B C N 166 173 166 126 139 132 101 110 136 43 40 45 
16 22 M 5 UM S B C N 167 174 190 140 131 155 96 113 128 46 40 38 
17 27 M 5 UM S A C N 161 170 156 112 132 143 101 112 127 47 42 37 
18 39 F 5 M NS B C N 164 168 176 126 134 146 96 116 122 48 45 39 
19 44 F 5 M NS B C N 163 181 165 127 131 147 15 117 127 43 44 39 
20 42 M 5 M S B C N 164 188 185 128 131 148 98 113 123 42 39 39 
21 38 M 5 M NS B C N 166 171 190 130 130 146 104 110 120 40 40 39 
22 21 M 5 UM S A C N 164 176 160 129 131 146 87 130 121 43 40 41 
23 43 F 5 M NS B C N 167 178 171 122 140 144 119 102 121 44 44 42 
24 47 M 5 M S B C N 161 171 175 122 121 143 102 87 127 46 36 38 
25 48 F 5 M NS B C N 160 173 177 124 140 146 101 119 112 42 44 38 
26 50 M 5 M NS A C N 164 172 174 121 121 170 104 115 125 44 41 39 
27 38 M 5 M S B C N 163 190 178 118 150 124 87 114 124 46 39 41 
28 39 M 5 M NS B C N 162 181 179 140 118 130 91 117 126 41 38 41 
29 39 M 5 M S B C N 169 162 176 136 131 151 114 112 121 40 39 42 
30 42 M 5 M NS A C N 170 167 174 112 134 138 98 113 122 44 41 38 
31 41 F 5 M NS B C N 165 162 176 110 130 165 118 116 122 43 41 39 
32 40 F 5 M NS B C N 178 168 179 127 135 141 78 114 126 43 42 37 
33 39 F 5 M NS B C N 145 170 180 128 131 140 91 117 123 44 38 43 
34 23 M 5 UM S B C N 160 170 160 112 130 141 99 118 110 42 42 39 
35 47 M 5 M S A C N 171 145 176 122 137 147 107 113 140 46 38 39 
36 39 F 5 M NS B C N 134 186 177 123 137 145 104 115 123 44 40 41 
37 45 M 5 M S B C N 181 156 177 124 138 146 101 114 138 43 40 39 
38 47 M 5 M S A C N 162 189 176 127 140 142 100 118 112 43 42 41 
39 49 F 5 M NS B C N 165 171 178 125 121 144 91 120 1227 41 38 39 
40 56 F 5 M NS B C N 164 172 179 128 159 141 92 121 126 42 40 38 
41 54 M 5 M S B C N 161 175 176 124 118 140 94 117 122 43 42 39 
42 57 M 5 M S B C N 160 171 180 127 137 165 107 112 128 44 41 37 
43 58 M 5 M S A C N 162 173 160 130 134 134 101 114 123 46 39 41 
44 60 F 5 M NS B C N 163 172 181 118 130 146 100 116 127 41 40 39 
45 51 M 5 M S A C N 167 181 164 122 132 144 81 117 124 43 41 39 
46 54 M 5 M S B C N 168 151 177 126 130 148 121 118 124 45 38 38 
47 57 F 5 M NS B C N 165 170 179 124 160 149 91 120 110 42 42 37 
48 59 F 5 M NS B C N 164 172 174 127 138 141 118 112 122 45 41 39 
49 53 F 5 M NS B C N 166 180 170 123 134 147 101 110 124 44 39 38 
50 55 F 5 M NS B C N 165 161 174 126 135 138 100 118 126 42 38 39 
51 23 F 3 UM NS B 260 N 167 202 198 127 158 178 118 137 151 43 38 38 
52 41 M 4 M S B 45 N 168 204 235 134 138 144 108 129 156 42 43 37 
53 33 F 1 M NS B 90 Y 169 198 223 124 175 176 114 136 129 40 37 41 
54 22 M 2 UM NS B 300 N 170 211 235 127 134 148 108 127 159 41 42 39 
55 24 F 1 UM NS B 154 Y 164 205 224 127 154 149 107 140 156 41 37 42 
56 26 M 3 M NS B 348 Y 163 192 200 126 158 140 114 128 128 42 37 38 
57 31 F 1 M NS B 111 N 167 207 231 123 156 165 108 128 149 41 40 39 
58 26 F 4 UM NS B 85 Y 165 208 265 124 141 186 100 130 161 40 41 38 
59 29 F 2 M NS B 167 Y 167 212 256 128 162 178 102 140 128 42 43 41 
60 24 M 1 UM NS B 90 N 164 210 212 126 158 149 111 139 154 41 37 42 
61 36 M 3 M S B 48 Y 167 201 231 122 155 148 105 140 153 41 42 44 
62 27 M 2 UM S B 250 Y 165 196 238 127 170 175 108 129 158 40 37 39 
63 34 F 1 M NS B 49 Y 169 278 197 126 156 144 118 141 129 41 36 36 
64 31 F 1 UM NS B 145 N 166 189 210 127 145 140 103 127 152 41 37 35 
65 48 M 4 M S B 275 Y 162 207 234 123 170 180 98 128 129 36 35 38 
66 43 M 3 M S B 35 Y 161 203 220 128 139 144 99 133 129 40 41 45 
67 36 F 4 M NS B 156 Y 165 198 236 118 160 165 106 141 127 40 37 39 
68 41 F 1 M NS B 240 Y 167 206 213 121 147 175 108 136 162 38 38 37 
69 45 F 2 M NS B 195 N 165 208 238 120 148 149 98 145 158 41 36 39 
70 50 M 1 M S B 90 Y 167 198 196 129 161 149 114 127 129 40 37 39 
71 49 F 4 M NS B 48 Y 164 208 238 131 164 148 106 130 130 36 37 39 
72 37 M 1 M S B 104 N 164 197 228 129 142 170 110 136 155 42 42 42 
73 39 F 4 M NS B 248 N 165 193 197 126 149 148 108 132 126 40 36 41 
74 24 M 1 UM S A 90 Y 167 201 187 128 138 168 107 121 165 40 41 39 
75 40 F 2 M NS B 40 Y 161 187 190 124 148 148 110 131 127 41 37 38 
76 43 F 3 M NS B 89 N 165 201 210 126 141 178 103 128 130 40 36 38 
77 50 F 4 M NS B 275 Y 164 209 265 132 175 168 104 137 129 41 37 41 
78 38 M 1 M S A 78 N 169 199 195 134 135 167 107 129 155 42 34 42 
79 37 F 2 M NS B 296 Y 164 198 190 132 149 187 106 127 156 36 42 38 
80 33 F 1 M NS B 42 N 164 195 186 132 149 148 101 137 129 40 41 41 
81 48 M 2 M NS A 95 Y 163 208 198 128 164 181 100 135 129 41 33 37 
82 45 F 2 M S B 80 Y 164 198 189 127 133 178 109 137 165 42 35 43 
83 48 F 3 M NS B 325 Y 165 208 196 128 144 171 102 129 128 41 42 39 
84 49 F 2 M NS B 175 Y 168 195 199 127 148 149 110 128 130 40 40 41 
85 36 M 4 M S B 134 Y 164 203 195 127 162 170 104 135 161 40 34 39 
86 39 M 2 M NS A 143 Y 165 198 200 127 149 150 107 129 127 41 41 41 
87 50 M 4 M S B 40 N 166 209 198 124 164 166 103 129 130 41 37 39 
88 44 M 2 M S B 97 Y 164 207 198 127 149 170 104 128 156 40 34 39 
89 41 M 4 M NS A 198 N 164 207 256 126 162 175 107 136 129 41 42 38 
90 44 M 4 M NS B 173 Y 165 198 190 128 158 180 110 128 156 42 43 39 
91 48 M 4 M S B 102 Y 167 198 236 125 144 156 107 129 156 41 33 37 
92 59 M 2 M NS A 87 Y 169 198 232 137 160 148 103 124 156 40 34 41 
93 51 M 4 M S B 134 Y 167 186 210 154 161 148 104 130 130 41 35 39 
94 60 M 4 M NS B 145 Y 166 175 198 141 141 149 107 133 161 40 36 38 
95 58 M 2 M S A 75 N 164 198 175 131 148 149 110 128 128 41 39 39 
96 53 M 2 M NS B 187 N 165 199 240 132 163 140 104 138 161 38 37 37 
97 55 M 4 M NS A 156 N 161 200 234 130 144 142 109 129 129 40 39 38 
98 58 M 4 M NS B 145 N 166 187 198 156 147 149 91 138 164 40 38 39 
99 59 M 4 M NS B 75 N 163 193 196 114 143 144 100 128 129 41 40 39 
100 60 F 4 M NS B 100 N 160 206 196 141 145 172 101 133 155 41 39 38 
 
